{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:21:58Z","timestamp":1789543318409,"version":"build-2803163510"},"reference-count":6,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,12,11]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Combination targeted therapy with vemurafenib and cobimetinib has proved effective for metastatic melanoma. However, severe cutaneous adverse reactions have been reported, most frequently not only drug rash with eosinophilia and systemic syndrome but also rare Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) cases. We report a case of life-threatening episode of TEN following metastatic melanoma targeted therapy with vemurafenib and cobimetinib, with a long but successful patient recovery.<\/jats:p>","DOI":"10.1136\/bcr-2024-263057","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T06:10:29Z","timestamp":1739686229000},"page":"e263057","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Toxic epidermal necrolysis caused by vemurafenib in a metastatic malignant melanoma"],"prefix":"10.1136","volume":"18","author":[{"given":"Duarte","family":"Flor","sequence":"first","affiliation":[{"name":"Dermatology Department, Coimbra Local Health Unit, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Pedroso","sequence":"additional","affiliation":[{"name":"Dermatology Department, Coimbra Local Health Unit, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Coutinho","sequence":"additional","affiliation":[{"name":"Dermatology Department, Coimbra Local Health Unit, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[{"name":"Dermatology Department, Coimbra Local Health Unit, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,16]]},"reference":[{"key":"2025082704044156000_18.2.e263057.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"2025082704044156000_18.2.e263057.2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061650","article-title":"Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation","volume":"12","author":"Meirson","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025082704044156000_18.2.e263057.3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jdv.16894","article-title":"Systematic review of BRAF\/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs)","volume":"35","author":"Torres-Navarro","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082704044156000_18.2.e263057.4","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13174","article-title":"Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma","volume":"33","author":"Poduje","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025082704044156000_18.2.e263057.5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jdcr.2018.08.003","article-title":"Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma","volume":"4","author":"Tahseen","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2025082704044156000_18.2.e263057.6","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/bjd.13522","article-title":"Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis","volume":"172","author":"Jeudy","year":"2015","journal-title":"Br J Dermatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-263057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:04:49Z","timestamp":1756292689000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-263057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":6,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,16]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bcr-2024-263057"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-263057","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}